iPS Cells & Regenerative Medicine– category –
-
iPSC Product Quality Defined in Differentiation: Core of Process Development for GMP Manufacturing
Made Scientific USA Overview Made Scientific highlights that the quality of iPSC-derived products is established during the differentiation development phase, making subsequent improvements challenging. Current differentiation protocols ... -
Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Life Science Tools for Cell and Gene Therapy Workflows
BioBucks United States Overview Merck KGaA has agreed to acquire life science tools provider Bio-Techne for $11.3 billion, a strategic move to significantly enhance its life science division. This acquisition deepens Merck KGaA's exposur... -
Typewriter Therapeutics Secures $56M Series A for In Vivo CAR-T, Aiming to Streamline Cell Therapy Manufacturing
BioBucks USA Overview Typewriter Therapeutics has raised $56 million in Series A funding to advance its innovative in vivo CAR-T cell therapy, designed to reprogram T cells directly within the patient's body. This approach eliminates the... -
CAR T-Cell Therapy Clinical Trial Landscape for Non-Hodgkin Lymphoma Expands with Over 70 Companies Developing Next-Gen Treatments
GlobeNewswire Global Overview A report by DelveInsight, released via GlobeNewswire, offers a detailed analysis of the CAR T-cell therapy clinical trial landscape for Non-Hodgkin Lymphoma (NHL). The report highlights over 70 companies adv... -
Global Cell and Gene Therapy Manufacturing Services Market to Surge to $31.3 Billion by 2035, Driven by Regulatory Modernization
openPR.com (DataM Intelligence) Global Overview According to DataM Intelligence, the global cell and gene therapy manufacturing services market is projected to reach $8.77 billion in 2026, growing rapidly to $31.3 billion by 2035 with a ... -
2026 iPSC Industry Report: Allogeneic Therapies Surpass Autologous, Diabetes, Parkinson’s, AMD Clinical Trials Progress
BioInformant Global Overview The 2026 iPSC Industry Report by BioInformant details advancements in iPSC technology for therapeutic applications, disease modeling, drug discovery, personalized medicine, and toxicity testing. Notably, allo... -
Cell and Gene Therapy GMP Services Market Forecast to Reach $5.88 Billion by 2030, Growing at 18.9% CAGR
The Business Research Company Global Overview The Business Research Company released a report forecasting the GMP services market for cell and gene therapy to reach $2.95 billion in 2026 and expand to $5.88 billion by 2030, exhibiting an... -
Beam Therapeutics’ Base Editing Therapy BEAM-302 Shows Rapid, Sustained AAT Increase in Phase 1/2 for Alpha-1 Antitrypsin Deficiency, Targets Accelerated Approval
GlobeNewswire / Beam Therapeutics Press Releases USA Overview Beam Therapeutics presented updated Phase 1/2 clinical data for its base editing therapy, BEAM-302, for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Socie... -
Sana Biotechnology Targets 2026 IND for iPSC-Derived Hypoimmune Pancreatic Islet Cell Therapy SC451 in Type 1 Diabetes
TipRanks / Sana Biotechnology, Inc. USA Overview Sana Biotechnology updated its investor presentation, emphasizing pipeline advancements, particularly for SC451, an iPSC-derived hypoimmune pancreatic islet cell therapy for Type 1 diabete... -
FDA Clears Clinical Trial for CAR T-Cell Therapy in Advanced Colorectal Cancer, Expanding Solid Tumor Reach
University of Colorado Anschutz USA Overview The U.S. Food and Drug Administration (FDA) has authorized researchers at the University of Colorado Anschutz to conduct a clinical trial for CAR T-cell therapy targeting advanced colorectal c...
